Cyxone, a leading biotech company focused on developing enhanced treatments specifically for autoimmune diseases, has reportedly announced that it plans to start a phase 2 clinical study to assess the efficacy of Rabeximod in COVID-19 infected patients. The new treatment is aimed at decreasing the risk of serious respiratory symptoms caused due to virus-associated overactivation of the patient’s immune system.

Most of the COVID-19 patients observe mild symptoms, however, in cases with severe symptoms, the immune system overreacts. This triggers a disproportional release of chemokines and cytokines leading to serious respiratory failure and hyperinflammation. Currently, there is no effective treatment available to tackle such a potentially lethal condition.

The initiation of the company’s clinical development program in people infected with COVID-19 is based on the findings of US entrepreneur and scientist Dr. Kalev Kask, who recognized Rabeximod’s potential to regulate the overactivation of the immune system in patients that have contracted life-threatening viruses, like Sars-Cov-2.

To develop and acquire every intellectual property of the COVID-19/Rabeximod project, Dr. Kask and Cyxone entered a new investment and development agreement back in June 10th of 2020.

Currently, the company working on regulatory applications to start the phase 2 clinical trial across a number of nations in Europe, a procedure that is supported by fast track programs that have been put in place by the government to advance the developments of COVID-19 treatments. The Phase 2 clinical study would be financed from existing company funds and proceeds acquired from previous directed share issues, which are a part of the deal with Kalev Kask. 

Meanwhile, the company is also working on the development of Rabeximod as a viable treatment for rheumatoid arthritis. The company has already completed a six-month toxicological study, and data analysis is presently under progress with an aim to release top-line outcomes later in fall.

Source credit: